OncoMatch/Clinical Trials/NCT04448184
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Is NCT04448184 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Tranexamic Acid for hematologic neoplasms.
Treatment: Tranexamic Acid — It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Lab requirements
Blood counts
Coagulopathy defined as a prothrombin time/INR or activated partial thromboplastin time more than 1.5 times the upper limit of normal or fibrinogen less than 2 g/L [excluded]
Kidney function
Significant renal impairment (creatinine more than 1.5 times the upper limit of normal or a eGFR less than 0.5 mL/min/1.78m2) [excluded]
Significant renal impairment (creatinine more than 1.5 times the upper limit of normal or a eGFR less than 0.5 mL/min/1.78m2); Coagulopathy defined as a prothrombin time/INR or activated partial thromboplastin time more than 1.5 times the upper limit of normal or fibrinogen less than 2 g/L; Active angina (chest pain of presumed cardiac origin either at rest or with activity) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify